Cargando…
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
Increases in bone mineral density (BMD) with osteoporosis treatment are associated with reduced fracture risk. Increasing BMD is therefore a goal of osteoporosis therapy. Here, we compare the probability of achieving a T‐score of > −2.5 over 3 years at the total hip (TH) or lumbar spine (LS) in w...
Autores principales: | Cosman, Felicia, Libanati, Cesar, Deignan, Cynthia, Yu, Zhigang, Wang, Zhenxun, Ferrari, Serge, Beck Jensen, Jens‐Erik, Peris, Pilar, Bertoldo, Francesco, Lespessailles, Eric, Hesse, Eric, Cummings, Steven R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567484/ https://www.ncbi.nlm.nih.gov/pubmed/34761149 http://dx.doi.org/10.1002/jbm4.10546 |
Ejemplares similares
-
Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022) -
T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
por: Cosman, Felicia, et al.
Publicado: (2020) -
Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019) -
Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
por: Langdahl, Bente, et al.
Publicado: (2022) -
Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)